Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has granted stock options to four newly-hired employees as employment inducements. The options total 141,800 shares of common stock with an exercise price of $3.64 per share, matching the closing price on June 30, 2025.
The options will vest over a four-year period, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Each option has a 10-year term and follows Akebia's inducement award program guidelines and Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA), un'azienda biofarmaceutica specializzata nelle malattie renali, ha concesso opzioni su azioni a quattro nuovi dipendenti come incentivo all'assunzione. Le opzioni ammontano a 141.800 azioni ordinarie con un prezzo di esercizio di 3,64 dollari per azione, corrispondente al prezzo di chiusura del 30 giugno 2025.
Le opzioni matureranno in un periodo di quattro anni, con il 25% che matura dopo il primo anno e il restante 75% che matura trimestralmente successivamente, subordinatamente alla continuazione del rapporto di lavoro. Ogni opzione ha una durata di 10 anni e segue le linee guida del programma di incentivi di Akebia e la Regola 5635(c)(4) del Nasdaq.
Akebia Therapeutics (Nasdaq: AKBA), una empresa biofarmacéutica centrada en enfermedades renales, ha otorgado opciones sobre acciones a cuatro empleados recién contratados como incentivo laboral. Las opciones suman 141,800 acciones ordinarias con un precio de ejercicio de $3.64 por acción, igualando el precio de cierre del 30 de junio de 2025.
Las opciones se consolidarán durante un período de cuatro años, con un 25% consolidado tras el primer año y el 75% restante consolidado trimestralmente después, condicionado a la continuidad del empleo. Cada opción tiene un plazo de 10 años y cumple con las directrices del programa de incentivos de Akebia y la Regla 5635(c)(4) de Nasdaq.
Akebia Therapeutics (나스닥: AKBA)는 신장 질환에 중점을 둔 바이오제약 회사로, 신규 채용 직원 4명에게 고용 유인책으로 주식매수선택권을 부여했습니다. 총 141,800주의 보통주 옵션이며, 행사 가격은 2025년 6월 30일 종가인 주당 3.64달러입니다.
옵션은 4년 기간에 걸쳐 권리가 부여되며, 첫 해 후 25%가 부여되고 나머지 75%는 이후 분기별로 부여되며 계속 고용 조건이 충족되어야 합니다. 각 옵션의 유효 기간은 10년이며, Akebia의 유인 보상 프로그램 지침과 나스닥 상장 규칙 5635(c)(4)를 따릅니다.
Akebia Therapeutics (Nasdaq : AKBA), une société biopharmaceutique spécialisée dans les maladies rénales, a accordé des options d'achat d'actions à quatre nouveaux employés en tant qu'incitations à l'embauche. Les options totalisent 141 800 actions ordinaires avec un prix d'exercice de 3,64 $ par action, correspondant au cours de clôture du 30 juin 2025.
Les options seront acquises sur une période de quatre ans, avec 25 % acquis après la première année et les 75 % restants acquis trimestriellement par la suite, sous réserve de la poursuite de l'emploi. Chaque option a une durée de 10 ans et respecte les directives du programme d'incitation d'Akebia ainsi que la règle 5635(c)(4) du Nasdaq.
Akebia Therapeutics (Nasdaq: AKBA), ein biopharmazeutisches Unternehmen mit Fokus auf Nierenerkrankungen, hat vier neu eingestellte Mitarbeiter Aktienoptionen als Einstellungsanreiz gewährt. Die Optionen umfassen insgesamt 141.800 Stammaktien mit einem Ausübungspreis von 3,64 USD pro Aktie, entsprechend dem Schlusskurs am 30. Juni 2025.
Die Optionen werden über einen Zeitraum von vier Jahren gestaffelt, wobei 25 % nach dem ersten Jahr und die verbleibenden 75 % danach vierteljährlich unter der Voraussetzung fortgesetzter Anstellung freigegeben werden. Jede Option hat eine Laufzeit von 10 Jahren und entspricht den Richtlinien von Akebias Anreizprogramm sowie der Nasdaq-Listing-Regel 5635(c)(4).
- None.
- None.
CAMBRIDGE, Mass., July 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 141,800 shares of Akebia’s common stock on June 30, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
What stock options did Akebia Therapeutics (AKBA) grant to new employees in June 2025?
What is the vesting schedule for Akebia Therapeutics' (AKBA) June 2025 employee stock options?
What is the exercise price of Akebia Therapeutics' (AKBA) June 2025 inducement grants?
How long do Akebia Therapeutics' (AKBA) June 2025 employee stock options last?
